Middle East Conflict Threatens ₹5,000 Crore in Indian Pharma Exports

Rising Geopolitical Tensions Impact Pharma Trade

Escalating tensions in the Middle East, particularly involving the United States, Israel, and Iran, have created uncertainty for global trade routes. India’s pharmaceutical sector is now facing significant risk as shipping disruptions and rising freight costs threaten exports to the region. Industry estimates suggest that Indian pharma exports worth up to ₹5,000 crore could be affected in March alone.

Warning from India’s Pharma Export Body

The Pharmaceuticals Export Promotion Council of India has raised serious concerns about the ongoing disruptions. According to industry leaders, continued instability in the region could lead to shipment delays or even temporary suspension of exports to key markets in the Gulf and West Asia. If the situation persists, exporters may face losses ranging between ₹2,500 crore and ₹5,000 crore.

Why the Middle East is Crucial for Indian Pharma

The Middle East is an important market for India’s pharmaceutical industry. Countries such as the UAE, Saudi Arabia, Oman, Kuwait, Qatar, and Bahrain rely heavily on Indian generic medicines. These nations collectively represent a significant portion of India’s pharmaceutical exports, making the region strategically important for both supply chains and revenue.

Shipping Routes and Freight Costs Under Pressure

The conflict has disrupted key maritime corridors used for transporting medicines. Concerns around the Strait of Hormuz and other shipping routes have forced logistics companies to reroute vessels or suspend operations. Freight rates have surged sharply, and war risk insurance premiums have also increased. These developments have significantly raised transportation costs for pharmaceutical exporters.

Challenges for Temperature Sensitive Medicines

Many pharmaceutical products require strict temperature control and timely delivery. Delays caused by longer shipping routes or logistical bottlenecks can compromise the quality of these medicines. As a result, exporters face the risk of financial losses and potential disruptions in medicine supply across importing countries.

Ripple Effects on the Pharma Supply Chain

The crisis could also increase costs for raw materials, packaging components, and intermediates used in drug manufacturing. Companies may be forced to absorb higher logistics expenses to maintain export commitments. This could reduce profit margins and create temporary supply shortages in markets that depend heavily on Indian medicines.

What Lies Ahead for the Industry

India’s pharmaceutical sector has historically shown resilience during global disruptions. However, prolonged instability in the Middle East could continue to strain export operations. Industry experts are closely monitoring developments and exploring alternative shipping routes and logistics strategies to minimize disruptions. The coming weeks will determine whether the impact remains temporary or evolves into a larger trade challenge.